REGN1033 vs Meldonium
Head-to-head comparison of REGN1033 (Trevogrumab (REGN1033)) and Meldonium (3-(2,2,2-Trimethylhydrazinium)propionate) — benefits, dosing, side effects, research data, and where to buy.
| Property | REGN1033 | Meldonium |
|---|---|---|
| Category | Muscle & Performance | Muscle & Performance |
| Full Name | Trevogrumab (REGN1033) | 3-(2,2,2-Trimethylhydrazinium)propionate |
| Molecular Weight | ~150 kDa | 146.19 Da |
| Half-Life | ~2-3 weeks | ~3-6 h |
| Amino Acids | N/A | N/A |
| Typical Dose | 100-300 mg SC or equivalent trial dosing | 500-1000 mg/day in divided oral doses |
| Route | Subcutaneous / Intravenous | Oral/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 60 | 70 |
| Research Status | Clinical | Clinical |
REGN1033 Benefits
- ✓myostatin blockade
- ✓lean-mass preservation
- ✓muscle hypertrophy support
- ✓catabolic-state countermeasure
Meldonium Benefits
- ✓improves exercise tolerance
- ✓may reduce ischemic fatigue
- ✓supports metabolic efficiency
- ✓may aid recovery
REGN1033 Dosing
SC or IV clinical-trial dosing|repeat every 2-4 weeks|dose escalation by study
Meldonium Dosing
500 mg orally daily|500 mg orally twice daily|500-1000 mg/day in divided doses
REGN1033 Side Effects
- ⚠injection-site reactions
- ⚠headache
- ⚠fatigue
Meldonium Side Effects
- ⚠GI upset
- ⚠headache
- ⚠palpitations
Research Overview
REGN1033
Human and animal studies indicate that myostatin neutralization can increase muscle size, though functional gains are often smaller than mass gains. Trevogrumab is part of the broader literature showing that selective myostatin inhibition can alter body composition in clinically meaningful ways.
Meldonium
Clinical literature focuses on cardiometabolic support and exercise tolerance rather than direct anabolic effects. Any endurance benefit is thought to come from altered substrate handling and improved tolerance to stress.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.